Rapid production of novel pre-MicroRNA agent hsa-mir-27b in escherichia coli using recombinant RNA technology for functional studies in mammalian cells

Mei Mei Li, Wei Peng Wang, Wen Juan Wu, Min Huang, Aiming Yu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Noncoding microRNAs (miRNAs or miRs) have been revealed as critical epigenetic factors in the regulation of various cellular processes, including drug metabolism and disposition. However, research on miRNA functions is limited to the use of synthetic RNA and recombinant DNA agents. Herein, we show that novel premiRNA-27b (miR-27b) agents can be biosynthesized in Escherichia coli using recombinant RNA technology, and recombinant transfer RNA (tRNA)/mir-27b chimera was readily purified to a high degree of homogeneity (>95%) using anion-exchange fast protein liquid chromatography. The tRNA-fusion miR-27b was revealed to be processed to mature miRNA miR-27b in human carcinoma LS-180 cells in a dose- and time-dependent manner. Moreover, recombinant tRNA/miR-27b agents were biologically active in reducing the mRNA and protein expression levels of cytochrome P450 3A4 (CYP3A4), which consequently led to lower midazolam 1′-hydroxylase activity. These findings demonstrate that pre-miRNA agents can be produced by recombinant RNA technology for functional studies. Copyright

Original languageEnglish (US)
Pages (from-to)1791-1795
Number of pages5
JournalDrug Metabolism and Disposition
Volume42
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

MicroRNAs
Escherichia coli
Technology
Transfer RNA
Antiporters
Technology Transfer
Cytochrome P-450 CYP3A
Recombinant DNA
Midazolam
Mixed Function Oxygenases
Epigenomics
Liquid Chromatography
recombinant RNA
RNA
Carcinoma
Messenger RNA
Research
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Rapid production of novel pre-MicroRNA agent hsa-mir-27b in escherichia coli using recombinant RNA technology for functional studies in mammalian cells. / Li, Mei Mei; Wang, Wei Peng; Wu, Wen Juan; Huang, Min; Yu, Aiming.

In: Drug Metabolism and Disposition, Vol. 42, No. 11, 01.11.2014, p. 1791-1795.

Research output: Contribution to journalArticle

@article{01a40f5d300d4434b156a18b280560de,
title = "Rapid production of novel pre-MicroRNA agent hsa-mir-27b in escherichia coli using recombinant RNA technology for functional studies in mammalian cells",
abstract = "Noncoding microRNAs (miRNAs or miRs) have been revealed as critical epigenetic factors in the regulation of various cellular processes, including drug metabolism and disposition. However, research on miRNA functions is limited to the use of synthetic RNA and recombinant DNA agents. Herein, we show that novel premiRNA-27b (miR-27b) agents can be biosynthesized in Escherichia coli using recombinant RNA technology, and recombinant transfer RNA (tRNA)/mir-27b chimera was readily purified to a high degree of homogeneity (>95{\%}) using anion-exchange fast protein liquid chromatography. The tRNA-fusion miR-27b was revealed to be processed to mature miRNA miR-27b in human carcinoma LS-180 cells in a dose- and time-dependent manner. Moreover, recombinant tRNA/miR-27b agents were biologically active in reducing the mRNA and protein expression levels of cytochrome P450 3A4 (CYP3A4), which consequently led to lower midazolam 1′-hydroxylase activity. These findings demonstrate that pre-miRNA agents can be produced by recombinant RNA technology for functional studies. Copyright",
author = "Li, {Mei Mei} and Wang, {Wei Peng} and Wu, {Wen Juan} and Min Huang and Aiming Yu",
year = "2014",
month = "11",
day = "1",
doi = "10.1124/dmd.114.060145",
language = "English (US)",
volume = "42",
pages = "1791--1795",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "11",

}

TY - JOUR

T1 - Rapid production of novel pre-MicroRNA agent hsa-mir-27b in escherichia coli using recombinant RNA technology for functional studies in mammalian cells

AU - Li, Mei Mei

AU - Wang, Wei Peng

AU - Wu, Wen Juan

AU - Huang, Min

AU - Yu, Aiming

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Noncoding microRNAs (miRNAs or miRs) have been revealed as critical epigenetic factors in the regulation of various cellular processes, including drug metabolism and disposition. However, research on miRNA functions is limited to the use of synthetic RNA and recombinant DNA agents. Herein, we show that novel premiRNA-27b (miR-27b) agents can be biosynthesized in Escherichia coli using recombinant RNA technology, and recombinant transfer RNA (tRNA)/mir-27b chimera was readily purified to a high degree of homogeneity (>95%) using anion-exchange fast protein liquid chromatography. The tRNA-fusion miR-27b was revealed to be processed to mature miRNA miR-27b in human carcinoma LS-180 cells in a dose- and time-dependent manner. Moreover, recombinant tRNA/miR-27b agents were biologically active in reducing the mRNA and protein expression levels of cytochrome P450 3A4 (CYP3A4), which consequently led to lower midazolam 1′-hydroxylase activity. These findings demonstrate that pre-miRNA agents can be produced by recombinant RNA technology for functional studies. Copyright

AB - Noncoding microRNAs (miRNAs or miRs) have been revealed as critical epigenetic factors in the regulation of various cellular processes, including drug metabolism and disposition. However, research on miRNA functions is limited to the use of synthetic RNA and recombinant DNA agents. Herein, we show that novel premiRNA-27b (miR-27b) agents can be biosynthesized in Escherichia coli using recombinant RNA technology, and recombinant transfer RNA (tRNA)/mir-27b chimera was readily purified to a high degree of homogeneity (>95%) using anion-exchange fast protein liquid chromatography. The tRNA-fusion miR-27b was revealed to be processed to mature miRNA miR-27b in human carcinoma LS-180 cells in a dose- and time-dependent manner. Moreover, recombinant tRNA/miR-27b agents were biologically active in reducing the mRNA and protein expression levels of cytochrome P450 3A4 (CYP3A4), which consequently led to lower midazolam 1′-hydroxylase activity. These findings demonstrate that pre-miRNA agents can be produced by recombinant RNA technology for functional studies. Copyright

UR - http://www.scopus.com/inward/record.url?scp=84907917954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907917954&partnerID=8YFLogxK

U2 - 10.1124/dmd.114.060145

DO - 10.1124/dmd.114.060145

M3 - Article

VL - 42

SP - 1791

EP - 1795

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 11

ER -